No Data
Xiaofang Pharmaceutical: Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Xiaofang Pharmaceutical (603207.SH): The net income in the first three quarters was 0.162 billion yuan, a 4.07% decrease compared to the same period last year.
GeLongHui October 28th | Xiao Fang Pharmaceuticals (603207.SH) announced the third quarter report of 2024, with a revenue of 0.367 billion yuan for the first three quarters, a year-on-year increase of 0.05%; net income attributable to shareholders of the listed company was 0.162 billion yuan, a year-on-year decrease of 4.07%; and basic earnings per share was 1.28 yuan.
Xiaofang Pharmaceutical (603207.SH): The company does not produce snake medicine.
On September 9, Gelonghui reported that Xiaofang Pharmaceutical (603207.SH) stated on the interactive platform that the company does not have snake medicine.
Chinese Shares Hold Steady Ahead of Manufacturing Data; Xiaofang Pharmaceutical Soars 167% on Debut
Shanghai Xiaofang Pharmaceutical Lists on Shanghai Bourse After 499-Million-Yuan IPO
